From start to finish, from cells to drugs, your research depends on the starting material’s quality.
Biological therapeutics largely depends on the use of human-based models early in the drug discovery process. Access to a diverse population of donors, well established and consistent protocols for the collection and preparation of human cells, and validation of the integrity of the cells maximize the efficiency and accuracy of the studies, especially analysis of gene and protein expression, and enhances the success of reaching the marketplace.
Donor accessibility and characterization and the quality of cells are unquestionably key to the successful development of new biological therapeutics for the treatment of a disease. With seven nationwide collection centers, our donor pool is one of the largest HLA-typed and most characterized in the industry, allowing readily available donors that suit your drug discovery and development criteria. Each of our Collection Centers houses an on-site state-of-the-art laboratory, providing an end-to-end service whereby cells are processed, isolated, and cryopreserved or shipped out fresh immediately after collection from a donor. Procedures and protocols involved in cell collection, processing, isolation, and analysis follow strict guidelines and quality standards, ensuring consistent, compliant, viable, and pure cells with guaranteed counts.
Clinical Grade Leukopaks®
Our new GMP-compliant Leukopaks® meet regulatory requirements for use in allogeneic cell-based therapies. Our state of the art facility and strict standard operating procedures ensure a clean environment and the highest quality of cell possible. Our products have been tested by the University of California, San Francisco, and are pending further audits from academic and federal agencies.